A corporate venture fund invests strategically on behalf of the parent company, which has a global presence. The firm is interested in life science opportunities globally, and expects to make 3-4 new investments per year. The firm typically invests about $10 million over the life of an investment.  The fund is typically a lead investor, and participates in syndicates with other investment firms. The firm does not attach rights or options to equity investments; the fund’s allocations are ‘no strings attached’. The firm considers opportunities globally but focuses on Europe, Middle East and North America.

The firm is strategically mandated to invest in opportunities with therapeutic platform technologies. The firm is only interested in novel technologies; while the fund will consider investing in any form of therapeutic technology, regenerative medicine, cell therapies and gene therapies are the areas of greatest interest. The fund is focused on investing in oncology (particularly immuno-oncology), but will also consider opportunities in other indication areas. The firm generally invests in preclinical assets.

The firm invests in technologies of strategic importance to the corporate. The firm only invests in privately held companies. The firm typically does not invest in single asset opportunities; only companies with multiple pipeline assets are of interest. The firm is often the first outside investor in a company, and prefers to invest in opportunities where the firm’s allocation can secure a meaningful stake in the company (a board seat is a requirement).

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital and private equity firm invests in breakthrough industrial technologies and, within the life sciences, is looking to invest in companies developing R&D and manufacturing tools and services. The firm is interested in companies that have at least some data through a pilot or a pharma partner to validate their technology. The firm invests primarily in North America-based companies, but will consider international companies that have significant operations in the US.

The firm invests in tools and services for R&D and manufacturing within the life sciences. This can include diagnostics platforms, AI/ML based drug discovery platforms, analytics or manufacturing tools. The firm invests primarily in technologies that do not require FDA approval, and looks for companies with some data validation of their technology with an external partner.

The firm prefers to lead and take a board seat when investing, but will occasionally co-invest as well. The firm will also consider follow-on investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in USA, with a partner in China that can provide support to companies interested in China market entry, has great experience with working with regulatory agencies to gain product approval for both FDA and CFDA. Since its establishment, the firm has invested in over 30 companies and continues to actively seek life science investments, aiming to invest in 8-10 companies per year. The firm usually participates in seed to series B financing rounds with check sizes between $500K – 2M and will consider companies based in USA and China.

The firm is opportunistic and will consider all early-stage opportunities in therapeutics, medical devices, diagnostics, and digital health, as long as the technology is considered highly disruptive. The firm’s greatest focus lies in the medical device sector in which the firm has the strongest expertise. In therapeutics, the firm will consider pre-clinical and phase I assets. In medical devices and diagnostics, the firm is open to all classes of medical devices including 510k and PMA that are in development or clinical trials. The firm has reviewed companies of various stages in the past: those that have just developed a valid prototype, and those that were already profitable prior to investment.

The firm seeks to work with companies with an experienced management team, ideally led by a serial entrepreneur with a successful track record. The firm can both lead and co-invest but prefers to lead financing rounds for medical device companies and will most likely take a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Founded in 2019, a Chinese venture capital firm specialized in the growth-stage life science investments and IT area. Currently, the firm has ~300 RMB assets under management. While generally being flexible on the allocation size, the firm typically makes investments ranging from 10-60 MM RMB (~1.4-8.5 MM USD).

The firm has strong interest in investing novel pharmaceuticals, including orphan drugs. Also, the firm is open to digital health, especially the ones has big data application in life science area. So far, the firm has no interest in diagnostics nor medical devices products.

The firm prefers companies with China Angle, especially the ones open to register an entity in China.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.